India, Aug. 3 -- Eli Lilly and Company (LLY), a pharmaceutical firm, on Monday announced the receipt of a Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for Olomorasib as a monotherapy in treating adult patients of advanced pancreatic cancer with a KRAS G12C mutation.
The Breakthrough Therapy status is granted to expedite the development and review of drugs that are intended to treat a serious condition, when said therapy shows proising preclinical or early clinical evidence for a particular indication.
Pancreatic cancer accounts for 60,000 new cases in the U.S. alone every year, with about 50,000 deaths reported annually. The cancer presents a poor prognosis, with the estimated five-year survival rate c...